Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
64
TSHA Quote, Financials, Valuation and Earnings
Last price:
$5.05
Seasonality move
:
-10.93%
Day range:
$5.01 - $5.24
52-week range:
$1.05 - $5.51
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
225.20x
P/B ratio:
6.32x
Volume:
3M
Avg. volume:
3.5M
1-year change:
112.18%
Market cap:
$1.4B
Revenue:
$8.3M
EPS (TTM):
-$0.35
Analysts' Opinion
-
Consensus RatingTaysha Gene Therapies, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.57, Taysha Gene Therapies, Inc. has an estimated upside of 109.34% from its current price of $5.05.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $5.05.
Fair Value
-
According to the consensus of 11 analysts, Taysha Gene Therapies, Inc. has 109.34% upside to fair value with a price target of $10.57 per share.
TSHA vs. S&P 500
-
Over the past 5 trading days, Taysha Gene Therapies, Inc. has overperformed the S&P 500 by 6.21% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Taysha Gene Therapies, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Taysha Gene Therapies, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Taysha Gene Therapies, Inc. reported revenues of --.
Earnings Growth
-
Taysha Gene Therapies, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Taysha Gene Therapies, Inc. reported earnings per share of -$0.09.
Enterprise value:
1.2B
EV / Invested capital:
--
Price / LTM sales:
225.20x
EV / EBIT:
--
EV / Revenue:
183.04x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-13.57x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$5.2M
Return On Assets:
-40.14%
Net Income Margin (TTM):
-1583.66%
Return On Equity:
-73.14%
Return On Invested Capital:
-49.9%
Operating Margin:
-1347.08%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $14.3M | $9.9M | $6.3M | $1.8M | -- | |
| Gross Profit | $11M | $8.6M | $5.2M | $1.5M | -$286K | |
| Operating Income | -$74.3M | -$82.5M | -$102.1M | -$21.1M | -$34M | |
| EBITDA | -$70.9M | -$81.2M | -$101M | -$20.8M | -$33.7M | |
| Diluted EPS | -$2.58 | -$0.03 | -$0.35 | -$0.10 | -$0.09 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $197.2M | $42.3M | $171.1M | $161.6M | $299.9M | |
| Total Assets | $241M | $111.5M | $195.8M | $180.2M | $316.6M | |
| Current Liabilities | $43.2M | $33.1M | $180.5M | $29.3M | $28.6M | |
| Total Liabilities | $100.6M | $100.3M | $244.9M | $91.4M | $97.6M | |
| Total Equity | $140.4M | $11.1M | -$49.1M | $88.8M | $219M | |
| Total Debt | $54.4M | $63.3M | $57.6M | $61.1M | $67.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$42.2M | -$79.1M | -$84.7M | -$21.6M | -$24.2M | |
| Cash From Investing | -$9.7M | -$386K | -$344K | -$35K | -$48K | |
| Cash From Financing | $181.9M | $72.8M | $224.7M | $6.6M | $8.8M | |
| Free Cash Flow | -$51.9M | -$79.4M | -$85.1M | -$21.7M | -$24.3M | |
TSHA
Sector
Market Cap
$1.4B
$28.5M
Price % of 52-Week High
91.68%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-24.35%
-1.33%
1-Year Price Total Return
112.19%
-20.32%
Beta (5-Year)
1.056
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.66
200-day SMA
Buy
Level
$2.88
Bollinger Bands (100)
Buy
Level
2.79 - 4.59
Chaikin Money Flow
Buy
Level
109.4M
20-day SMA
Buy
Level
$4.33
Relative Strength Index (RSI14)
Buy
Level
60.66
ADX Line
Buy
Level
15.88
Williams %R
Sell
Level
-14.3396
50-day SMA
Buy
Level
$4.49
MACD (12, 26)
Buy
Level
0.20
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
92.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.5138)
Sell
CA Score
(Annual)
Level (-2.9492)
Buy
Beneish M-Score
(Annual)
Level (-3.9494)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.751)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
Stock Forecast FAQ
In the current month, TSHA has received 11 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TSHA average analyst price target in the past 3 months is $10.57.
-
Where Will Taysha Gene Therapies, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Taysha Gene Therapies, Inc. share price will rise to $10.57 per share over the next 12 months.
-
What Do Analysts Say About Taysha Gene Therapies, Inc.?
Analysts are divided on their view about Taysha Gene Therapies, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Taysha Gene Therapies, Inc. is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Taysha Gene Therapies, Inc.'s Price Target?
The price target for Taysha Gene Therapies, Inc. over the next 1-year time period is forecast to be $10.57 according to 11 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TSHA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Taysha Gene Therapies, Inc. is a Buy. 11 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TSHA?
You can purchase shares of Taysha Gene Therapies, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Taysha Gene Therapies, Inc. shares.
-
What Is The Taysha Gene Therapies, Inc. Share Price Today?
Taysha Gene Therapies, Inc. was last trading at $5.05 per share. This represents the most recent stock quote for Taysha Gene Therapies, Inc.. Yesterday, Taysha Gene Therapies, Inc. closed at $5.05 per share.
-
How To Buy Taysha Gene Therapies, Inc. Stock Online?
In order to purchase Taysha Gene Therapies, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TSHA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TSHA
Sector
P/E ratio
--
23.75x
PEG ratio
-0.02x
-0.01x
P/B ratio
6.32x
1.83x
Price / LTM sales
225.20x
1.60x
Growth Metrics
TSHA
Sector
Revenue growth
-100%
4.85%
Earnings growth
2.83%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.10
-$0.20
Profitability
TSHA
Sector
Profitability FY 2024
$7.1M
$3.6M
Return on invested capital
-49.9%
-30.98%
Return on assets
-40.14%
-27.62%
Return on equity
-73.14%
-36.69%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
3
Balance Sheet
TSHA
Sector
Total cash
$297.8M
$27.2M
Short term investments
--
$25.7M
Total assets
$276.4M
$79.7M
Long term debt
$67.8M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
